News about Global Pharma

FDA Accepts Novo Nordisk's NDA for Oral Wegovy for Chronic Weight Management and Heart Risk Reduction

The FDA application is based on results from OASIS 4, a 64-week phase 3 randomized, controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI >/= 30 kg/m2) or overweight (BMI >/= 27 kg/m2) with one or more comorbidities. Patients with diabetes were excluded.

Global Pharma | 05/05/2025 | By Manvi |  375

Turn Therapeutics Reaches Milestone in Cold-Storage-Free Vaccine Development

In partnership with the nonprofit International AIDS Vaccine Initiative, Turn Therapeutics has validated a standardized assay and demonstrated 100 percent recovery of vesicular stomatitis virus (VSV) -- a widely used viral backbone in vaccine development -- after both 24 and 72 hours in its proprietary oil-based carrier at room temperature.

Global Pharma | 05/05/2025 | By Manvi |  292

Solvent Direct Launches Cannabis Extraction Safety Program with LSI and CARMA365

Solvent Direct has officially partnered with the Laboratory Safety Institute (LSI) and CARMA365 Insurance to launch a powerful safety and certification program tailored specifically for cannabis extraction professionals.

Global Pharma | 03/05/2025 | By Manvi |  263

USMGC Leases Ohio Facility to Finalize All-American Glove Supply Chain

This critical move marks the final phase in USMGC's mission to build and secure a 100 percent American-made medical and surgical glove supply chain—free from reliance on China or any foreign supplier.

Global Pharma | 03/05/2025 | By Manvi |  423

Alembic Pharmaceuticals Secures USFDA Approval for Ticagrelor Tablets

Alembic Pharmaceuticals has received USFDA final approval for Ticagrelor Tablets, 90 mg, and tentative approval for 60 mg.

Global Pharma | 03/05/2025 | By Manvi |  406

SMS Pharma's Vizag Plant Secures WHO Geneva Prequalification Approval

SMS Pharmaceuticals’ Unit VII facility in Visakhapatnam has received WHO Geneva prequalification, boosting its global regulatory credentials and market access for Anti-Retroviral APIs.

Global Pharma | 03/05/2025 | By Manvi |  487

FaceHeart Corporation Gets FDA 510(k) Clearance for FaceHeart Vitals

FaceHeart Corporation (FaceHeart), an AI health tech company, has received another FDA 510(k) clearance for FaceHeart Vitals™, its contactless video-based vital sign solution.

Global Pharma | 02/05/2025 | By Manvi |  658

Winter Park Chiropractor Introduces EXOMIND Brain Stimulation for Mental Health and Emotional Relief

Individuals suffering from depression, stress or mental fog can find relief at Winter Park Chiropractor, the office of Dr. Andrew Hull. This state-of-the-art chiropractic clinic is now offering EXOMIND, a cutting-edge treatment enhancing mental health and emotional regulation through non-invasive brain stimulation.

Global Pharma | 02/05/2025 | By Manvi |  332

S&E bio Secures Korea's First Approval for Exosome-Based Therapy Clinical Trial

S&E bio Co. Ltd. has received Korea's Ministry of Food and Drug Safety (MFDS) approval to begin Phase 1b clinical trial of an exosome-based therapy, SNE-101. The exosomes carry therapeutic microRNAs designed to enhance neuroregeneration.

Global Pharma | 02/05/2025 | By Manvi |  366

RoosterBio, Thermo Fisher Scientific Partner to Advance Cell and Exosome Therapy Manufacturing

RoosterBio has partnered with Thermo Fisher Scientific to accelerate the development and manufacturing of advanced cell and exosome therapies for degenerative diseases, combining hMSC expertise with GMP manufacturing capabilities.

Global Pharma | 02/05/2025 | By Manvi |  287